# VNDA catalysts: Vanda Pharmaceuticals Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/vnda/catalysts

> Vanda Pharmaceuticals Inc. (VNDA) has 17 upcoming catalysts. The next is the VQW-765 primary completion, December 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only, year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | Vanda Pharmaceuticals Inc. |
| Ticker | VNDA (Nasdaq) |
| SEC CIK | 1347178 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/vnda |

## Cash runway

Cash $61.9M as of 2026-09-30; quarterly burn $28.4M; about 6.5 months of runway at that rate (XBRL company facts, accession 0001347178-26-000002).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Sep 2022 | [HETLIOZ® (tasimelteon) NDA/BLA submission](https://sec-api.dev/pdufa/tasimelteon) | VNDA | jet lag disorder | completed | "In September 2022, the Company filed a lawsuit in the DC District Court against the FDA to compel the FDA to comply with two separate non-discretionary obligations under the FDCA and its implementing regulations: an obligation to publish a notice of an opportunity for a hearing on the Company's sNDA for HETLIOZ® in the treatment of jet lag disorder in the Federal Register within 180 days of the filing of the sNDA, and a separate obligation to publish the same notice within 60 days of the request for a hearing." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1347178/000162828025047317/vnda-20250930.htm)) |
| Dec 2022 | [Generic FDA approval](https://sec-api.dev/pdufa/generic) | VNDA |  | completed, approved | "For HETLIOZ®, the FDA has approved ANDAs for Teva and Apotex, both of which have since launched their generic versions of HETLIOZ® at risk in the U.S. In December 2022, the U.S. District Court for the District of Delaware (Delaware District Court) ruled in favor of Teva and Apotex in our patent litigation relating to their filing of ANDAs for generic versions of HETLIOZ® in the U.S. The Federal Circuit affirmed this ruling, and the U.S. Supreme Court denied our petition for a writ of certiorari in April 2024." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1347178/000162828025005761/vnda-20241231.htm)) |
| Dec 2022 | [HETLIOZ® (tasimelteon) FDA approval](https://sec-api.dev/pdufa/tasimelteon) | VNDA |  | completed, approved | "In December 2022, the Company filed patent infringement lawsuits, including Hatch-Waxman Act claims, against each of Teva and Apotex in the U.S. District Court for the District of New Jersey (NJ District Court) asserting that U.S. Patent No. 11,285,129, a method of administration patent that was not litigated in the Delaware District Court cases ('129 Patent), will be infringed by Teva's and Apotex' generic versions of HETLIOZ®, each of which was approved by the FDA." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1347178/000162828025036861/vnda-20250630.htm)) |
| Jul 2023 | [HETLIOZ® (tasimelteon) NDA/BLA acceptance](https://sec-api.dev/pdufa/tasimelteon) | VNDA |  | completed | "In July 2023, the FDA accepted our sNDA for HETLIOZ® in insomnia for filing and set a PDUFA target action date of March 4, 2024 for its decision." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1347178/000162828026007460/vnda-20251231.htm)) |
| Dec 2023 | [NEREUSTM (tradipitant) FDA approval](https://sec-api.dev/pdufa/tradipitant) | VNDA | vomiting induced | completed, approved | "We have paid Lilly $5.0 million in upfront fees and development milestones, including a $2.0 million development milestone paid in December 2023 for the filing of the first marketing authorization for NEREUSTM in the U.S. or the E.U. In the fourth quarter of 2025, our NDA for the prevention of vomiting induced by motion was approved by the FDA and we accrued $10.0 million as a current liability as of December 31, 2025." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1347178/000162828026007460/vnda-20251231.htm)) |
| Dec 2023 | [NEREUSTM (tradipitant) NDA/BLA acceptance](https://sec-api.dev/pdufa/tradipitant) | VNDA |  | completed | "In December 2023, the FDA accepted our NDA for NEREUSTM in gastroparesis for filing and set a PDUFA target action date of September 18, 2024." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1347178/000162828026007460/vnda-20251231.htm)) |
| Jan 2024 | [VCA-894A FDA approval](https://sec-api.dev/pdufa/vca-894a) | VNDA | patient with CMT2S | completed, approved | "In January 2024, we announced that the FDA had approved the IND application to evaluate VCA-894A for the treatment of a patient with CMT2S. CMT2S is a rare subtype of Charcot-Marie-Tooth disease (CMT), an inherited peripheral neuropathy for which there is no available treatment." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1347178/000162828026007460/vnda-20251231.htm)) |
| Jan 2024 | [VTR-297 FDA approval](https://sec-api.dev/pdufa/vtr-297) | VNDA | onychomycosis, a fungal infection of the nail | completed, approved | "In January 2024, the FDA approved our IND application to evaluate VTR-297 for the treatment of onychomycosis, a fungal infection of the nail." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1347178/000162828026007460/vnda-20251231.htm)) |
| March 4, 2024 | [HETLIOZ® (tasimelteon) PDUFA date](https://sec-api.dev/pdufa/tasimelteon) | VNDA |  | scheduled | "In July 2023, the FDA accepted our sNDA for HETLIOZ® in insomnia for filing and set a target action date of March 4, 2024 under the Prescription Drug User Fee Act (PDUFA) for its decision." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1347178/000162828025005761/vnda-20241231.htm)) |
| March 4, 2024 | [Vanda Pharmaceuticals Inc. complete response letter (CRL)](https://sec-api.dev/companies/vnda/catalysts) | VNDA |  | completed, complete response letter | "On March 4, 2024, we received a CRL from the FDA." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1347178/000162828026007460/vnda-20251231.htm)) |
| September 18, 2024 | [NEREUSTM (tradipitant) complete response letter (CRL)](https://sec-api.dev/pdufa/tradipitant) | VNDA |  | completed, complete response letter | "On September 18, 2024, we received a CRL from the FDA." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1347178/000162828025005761/vnda-20241231.htm)) |
| September 18, 2024 | [NEREUSTM (tradipitant) PDUFA date](https://sec-api.dev/pdufa/tradipitant) | VNDA | symptoms of gastroparesis to a final decision prior | completed, complete response letter | "In December 2023, the FDA accepted our NDA for NEREUSTM in gastroparesis for filing and set a PDUFA target action date of September 18, 2024." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1347178/000162828026007460/vnda-20251231.htm)) |
| Dec 2024 | [Generic FDA approval](https://sec-api.dev/pdufa/generic) | VNDA |  | completed, approved | "In December 2024, the Company filed a lawsuit in the Delaware District Court against each of Teva and Apotex asserting U.S. Patent No. 11,918,556 ('556 Patent), a method of administration patent that was not litigated in the prior Delaware District Court cases, will be infringed by Teva's and Apotex's generic versions of HETLIOZ®, each of which was approved by the FDA." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1347178/000162828026007460/vnda-20251231.htm)) |
| Dec 2024 | [HETLIOZ® (tasimelteon) FDA approval](https://sec-api.dev/pdufa/tasimelteon) | VNDA |  | completed, approved | "In December 2024, the Company filed a lawsuit in the Delaware District Court against each of Teva and Apotex asserting U.S. Patent No. 11,918,556 ('556 Patent), a method of administration patent that was not litigated in the prior Delaware District Court cases, will be infringed by Teva's and Apotex's generic versions of HETLIOZ®, each of which was approved by the FDA." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1347178/000134717826000002/vnda-20260930.htm)) |
| Q1 2025 | [Bipolar NDA/BLA submission](https://sec-api.dev/pdufa/bipolar) | VNDA |  | scheduled | "•Vanda expects to submit a New Drug Application (NDA) for Bysanti™ to the U.S. Food and Drug Administration (FDA) for the treatments of acute bipolar I disorder and schizophrenia in the first quarter of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1347178/000162828025005406/vnda8-k2132025exhibit991.htm)) |
| January 7, 2025 | [NEREUSTM (tradipitant) NDA/BLA acceptance](https://sec-api.dev/pdufa/tradipitant) | VNDA |  | completed | "Separately, under the FDCA, the FDA has an obligation to commence a hearing on the Company's NDA for NEREUSTM in gastroparesis within 120 days of a timely accepted notice of opportunity for a hearing, which the FDA issued on January 7, 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1347178/000134717826000002/vnda-20260930.htm)) |
| February 13, 2025 | [Vanda Pharmaceuticals Inc. earnings report](https://sec-api.dev/companies/vnda/catalysts) | VNDA |  | completed | "Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1347178/000162828025005406/vnda8-k2132025exhibit991.htm)) |
| Apr 2025 | [NEREUSTM (tradipitant) NDA/BLA submission](https://sec-api.dev/pdufa/tradipitant) | VNDA |  | completed | "In April 2025, the Company filed a motion for summary judgment regarding its motion sickness NDA and requested to file summary judgment regarding its gastroparesis NDA." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1347178/000162828025047317/vnda-20250930.htm)) |
| May 2025 | [Fanapt® (iloperidone) NDA/BLA acceptance](https://sec-api.dev/pdufa/iloperidone) | VNDA |  | completed | "The FDA accepted our New Drug Application (NDA) for BysantiTM for the treatment of bipolar I disorder and schizophrenia for filing in May 2025 and set a PDUFA target action date of February 21, 2026." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1347178/000162828026007460/vnda-20251231.htm)) |
| May 7, 2025 | [Vanda Pharmaceuticals Inc. earnings report](https://sec-api.dev/companies/vnda/catalysts) | VNDA |  | completed | "Vanda Pharmaceuticals Reports First Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1347178/000162828025023154/vnda8-k572025exhibit991.htm)) |
| June 2025 | [HETLIOZ® (tasimelteon) primary completion](https://sec-api.dev/pdufa/tasimelteon) | VNDA | Sleep Wake Disorders; Sleep Disorders, Circadian Rhythm; Chronobiology Disorders | delayed | "NCT06701396 (Evaluating the Effects of Tasimelteon Vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD) and the CRY1Δ11 Variant): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2025-06-30 (ESTIMATED); Lead Sponsor Vanda Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06701396)) |
| July 2025 | [Tasimelteon oral capsule, tasimelteon liquid suspension primary completion](https://sec-api.dev/pdufa/tasimelteon-oral-capsule-tasimelteon-liquid-suspension) | VNDA | Autism Spectrum Disorder; Sleep Disorder; Neurological Disorder | delayed | "NCT05361707 (Evaluating the Effects of Tasimelteon in Individuals With Autism Spectrum Disorder (ASD) and Sleep Disturbances): Overall Status UNKNOWN; Phase PHASE3; Primary Completion 2025-07 (ESTIMATED); Lead Sponsor Vanda Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05361707)) |
| July 31, 2025 | [Vanda Pharmaceuticals Inc. earnings report](https://sec-api.dev/companies/vnda/catalysts) | VNDA |  | completed | "Vanda Pharmaceuticals Reports Second Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1347178/000162828025036843/vnda8-k7312025exhibit991.htm)) |
| October 6, 2025 | [NEREUSTM (tradipitant) primary completion](https://sec-api.dev/pdufa/tradipitant) | VNDA | Obesity | completed | "NCT06804603 (A Study to Measure the Effects of Using Tradipitant on Nausea and Vomiting After GLP-1R Agonist Use): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-10-06 (ACTUAL); Lead Sponsor Vanda Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06804603)) |
| October 29, 2025 | [Vanda Pharmaceuticals Inc. earnings report](https://sec-api.dev/companies/vnda/catalysts) | VNDA |  | completed | "Vanda Pharmaceuticals Reports Third Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1347178/000162828025047112/vnda8-k10292025exhibit991.htm)) |
| Dec 2025 | [Imsidolimab NDA/BLA submission](https://sec-api.dev/pdufa/imsidolimab) | VNDA |  | completed | "In December 2025, we submitted the Biologics License Application (BLA) for imsidolimab for the treatment of GPP and requested priority review of the BLA." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1347178/000162828026007460/vnda-20251231.htm)) |
| December 30, 2025 | [NEREUSTM (tradipitant) PDUFA date](https://sec-api.dev/pdufa/tradipitant) | VNDA | motion sickness | completed, approved | "Separately, the ongoing review of the pending, fully completed New Drug Application for tradipitant for the prevention of vomiting induced by motion remains on track, with a PDUFA target action date of December 30, 2025, positioning tradipitant as potentially the first new pharmacologic treatment for motion sickness in over 40 years." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1347178/000162828025055393/vnda8-k1242025exhibit991.htm)) |
| December 30, 2025 | [NEREUSTM (tradipitant) NDA/BLA acceptance](https://sec-api.dev/pdufa/tradipitant) | VNDA | motion sickness | scheduled | "•The NDA for tradipitant for the treatment of motion sickness was accepted for filing by the FDA with a PDUFA target action date of December 30, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1347178/000162828025023154/vnda8-k572025exhibit991.htm)) |
| December 30, 2025 | [NEREUSTM (tradipitant) FDA approval](https://sec-api.dev/pdufa/tradipitant) | VNDA | vomiting induced | completed, approved | "On December 30, 2025, Vanda Pharmaceuticals Inc. issued a press release announcing that the U.S. Food and Drug Administration has approved NEREUSTM (tradipitant) for the prevention of vomiting induced by motion." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1347178/000162828025059155/vnda-20251230.htm)) |
| 2026 | [Vanda Pharmaceuticals Inc. topline data readout](https://sec-api.dev/companies/vnda/catalysts) | VNDA |  | scheduled | "•Vanda's ongoing late-stage clinical studies are progressing rapidly and are expected to generate topline results in 2026 or early 2027, including:" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1347178/000162828026053308/vnda8-k852026exhibit991.htm)) |
| February 11, 2026 | [Vanda Pharmaceuticals Inc. earnings report](https://sec-api.dev/companies/vnda/catalysts) | VNDA |  | completed | "Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1347178/000162828026007256/vnda8-k2112026exhibit991.htm)) |
| February 20, 2026 | [BYSANTITM (milsaperidone) FDA approval](https://sec-api.dev/pdufa/milsaperidone) | VNDA | schizophrenia in adults | completed, approved | "On February 20, 2026, Vanda Pharmaceuticals Inc. ("Vanda") issued a press release announcing that the U.S. Food and Drug Administration has approved BysantiTM (milsaperidone) for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults and the treatment of schizophrenia in adults." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1347178/000162828026010376/vnda-20260220.htm)) |
| February 21, 2026 | [BYSANTITM (milsaperidone) PDUFA date](https://sec-api.dev/pdufa/milsaperidone) | VNDA |  | completed, approved | "•BysantiTM (milsaperidone) NDA for bipolar I disorder and schizophrenia under review by the FDA; PDUFA target action date of February 21, 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1347178/000162828026007256/vnda8-k2112026exhibit991.htm)) |
| February 21, 2026 | [Imsidolimab NDA/BLA submission](https://sec-api.dev/pdufa/imsidolimab) | VNDA |  | scheduled | ""We are particularly encouraged by our advancing pipeline, with multiple near-term regulatory milestones: the tradipitant NDA for motion sickness under FDA review with a PDUFA target action date of December 30, 2025; the Bysanti NDA for bipolar I disorder and schizophrenia also under FDA review with a PDUFA target action date of February 21, 2026; and the anticipated Q4 submission of the imsidolimab BLA for generalized pustular psoriasis." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1347178/000162828025047112/vnda8-k10292025exhibit991.htm)) |
| February 21, 2026 | [Bysanti (bysanti) PDUFA date](https://sec-api.dev/pdufa/bysanti) | VNDA |  | scheduled | "•Bysanti™ NDA for bipolar I disorder and schizophrenia is under review by the FDA with a PDUFA target action date of February 21, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1347178/000162828025047112/vnda8-k10292025exhibit991.htm)) |
| February 21, 2026 | [Bysanti (bysanti) NDA/BLA acceptance](https://sec-api.dev/pdufa/bysanti) | VNDA |  | scheduled | "•Bysanti™ NDA for bipolar I disorder and schizophrenia accepted for filing by the FDA with a PDUFA target action date of February 21, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1347178/000162828025023154/vnda8-k572025exhibit991.htm)) |
| March 30, 2026 | [NEREUSTM (tradipitant) primary completion](https://sec-api.dev/pdufa/tradipitant) | VNDA | Idiopathic Gastroparesis; Diabetic Gastroparesis; Gastroparesis | completed | "NCT06836557 (Open Label Safety Study of Tradipitant in Idiopathic and Diabetic Gastroparesis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-03-30 (ACTUAL); Lead Sponsor Vanda Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06836557)) |
| May 6, 2026 | [Vanda Pharmaceuticals Inc. earnings report](https://sec-api.dev/companies/vnda/catalysts) | VNDA |  | completed | "Vanda Pharmaceuticals Reports First Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1347178/000162828026031241/vnda8-k562026exhibit991.htm)) |
| August 5, 2026 | [Vanda Pharmaceuticals Inc. earnings report](https://sec-api.dev/companies/vnda/catalysts) | VNDA |  | completed | "Vanda Pharmaceuticals Reports Second Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1347178/000162828026053308/vnda8-k852026exhibit991.htm)) |
| Sep 2026 | [HETLIOZ® (tasimelteon) topline data readout](https://sec-api.dev/pdufa/tasimelteon) | VNDA | Delayed Sleep-Wake Phase Disorder | completed, positive | "•In September 2026, Vanda announced positive topline results from the pivotal Phase III study of HETLIOZ® in adults with Delayed Sleep-Wake Phase Disorder (DSWPD)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1347178/000162828026067886/vnda8-k10282026exhibit991.htm)) |
| September 2026 | [Trichostatin a primary completion](https://sec-api.dev/pdufa/trichostatin-a) | VNDA | Onychomycosis of Toenail | delayed | "NCT07065773 (Safety, Tolerability and Efficacy of Trichostatin A in Patients With Mild to Severe Onychomycosis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-09 (ESTIMATED); Lead Sponsor Vanda Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07065773)) |
| Sep to Dec 2026 | [Trichostatin a topline data readout](https://sec-api.dev/pdufa/trichostatin-a) | VNDA | Onychomycosis of Toenail | scheduled | "NCT07065773 (Safety, Tolerability and Efficacy of Trichostatin A in Patients With Mild to Severe Onychomycosis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-09 (ESTIMATED); Lead Sponsor Vanda Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07065773)) |
| September 2026 | [VSJ-110 primary completion](https://sec-api.dev/pdufa/vsj-110) | VNDA | Dry Eye | delayed | "NCT07179055 (An Eight-Week Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-09 (ESTIMATED); Lead Sponsor Vanda Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07179055)) |
| Sep to Dec 2026 | [VSJ-110 topline data readout](https://sec-api.dev/pdufa/vsj-110) | VNDA | Dry Eye | scheduled | "NCT07179055 (An Eight-Week Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-09 (ESTIMATED); Lead Sponsor Vanda Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07179055)) |
| September 4, 2026 | [HETLIOZ® (tasimelteon) primary completion](https://sec-api.dev/pdufa/tasimelteon) | VNDA | Sleep Wake Disorders; Sleep Disorders, Circadian Rhythm; Chronobiology Disorders | completed | "NCT04652882 (Evaluating the Effects of Tasimelteon vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-09-04 (ACTUAL); Lead Sponsor Vanda Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04652882)) |
| Sep to Dec 2026 | [HETLIOZ® (tasimelteon) topline data readout](https://sec-api.dev/pdufa/tasimelteon) | VNDA | Sleep Wake Disorders; Sleep Disorders, Circadian Rhythm; Chronobiology Disorders | scheduled | "NCT04652882 (Evaluating the Effects of Tasimelteon vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-09-04 (ACTUAL); Lead Sponsor Vanda Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04652882)) |
| October 2026 | [Fanapt® (iloperidone) primary completion](https://sec-api.dev/pdufa/iloperidone) | VNDA | Hypertension; Uncontrolled Hypertension | delayed | "NCT07090161 (Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-10 (ESTIMATED); Lead Sponsor Vanda Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07090161)) |
| Oct 2026 to Jan 2027 | [Fanapt® (iloperidone) topline data readout](https://sec-api.dev/pdufa/iloperidone) | VNDA | Hypertension; Uncontrolled Hypertension | scheduled | "NCT07090161 (Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-10 (ESTIMATED); Lead Sponsor Vanda Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07090161)) |
| October 28, 2026 | [Vanda Pharmaceuticals Inc. earnings report](https://sec-api.dev/companies/vnda/catalysts) | VNDA |  | completed | "Vanda Pharmaceuticals Reports Third Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1347178/000162828026067886/vnda8-k10282026exhibit991.htm)) |
| December 2026 | [VQW-765 primary completion](https://sec-api.dev/pdufa/vqw-765) | VNDA | Social Anxiety Disorder (SAD) | scheduled | "NCT07221578 (Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety Disorder): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Vanda Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07221578)) |
| Dec 2026 to Mar 2027 | [VQW-765 topline data readout](https://sec-api.dev/pdufa/vqw-765) | VNDA | Social Anxiety Disorder (SAD) | scheduled | "NCT07221578 (Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety Disorder): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Vanda Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07221578)) |
| December 2026 | [NEREUSTM (tradipitant) primary completion](https://sec-api.dev/pdufa/tradipitant) | VNDA | Nausea and Vomiting; Obesity | scheduled | "NCT07446439 (A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12-01 (ESTIMATED); Lead Sponsor Vanda Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07446439)) |
| Dec 2026 to Mar 2027 | [NEREUSTM (tradipitant) topline data readout](https://sec-api.dev/pdufa/tradipitant) | VNDA | Nausea and Vomiting; Obesity | scheduled | "NCT07446439 (A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12-01 (ESTIMATED); Lead Sponsor Vanda Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07446439)) |
| December 12, 2026 | [Imsidolimab PDUFA date](https://sec-api.dev/pdufa/imsidolimab) | VNDA |  | scheduled | "•QuimilzaTM (imsidolimab) BLA for GPP under review by the FDA; PDUFA target action date of December 12, 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1347178/000162828026053308/vnda8-k852026exhibit991.htm)) |
| Sep to Dec 2027 | [NEREUSTM (tradipitant) topline data readout](https://sec-api.dev/pdufa/tradipitant) | VNDA | Motion Sickness | scheduled | "NCT06138613 (Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-09-30 (ESTIMATED); Lead Sponsor Vanda Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06138613)) |
| September 2027 | [NEREUSTM (tradipitant) primary completion](https://sec-api.dev/pdufa/tradipitant) | VNDA | Motion Sickness | scheduled | "NCT06138613 (Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-09-30 (ESTIMATED); Lead Sponsor Vanda Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06138613)) |
| November 2027 | [Tasimelteon oral suspension primary completion](https://sec-api.dev/pdufa/tasimelteon-oral-suspension) | VNDA | Insomnia Disorder | scheduled | "NCT06953869 (Evaluating the Effects of Tasimelteon vs. Placebo in Treating Pediatric Insomnia): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-11 (ESTIMATED); Lead Sponsor Vanda Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06953869)) |
| Nov 2027 to Feb 2028 | [Tasimelteon oral suspension topline data readout](https://sec-api.dev/pdufa/tasimelteon-oral-suspension) | VNDA | Insomnia Disorder | scheduled | "NCT06953869 (Evaluating the Effects of Tasimelteon vs. Placebo in Treating Pediatric Insomnia): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-11 (ESTIMATED); Lead Sponsor Vanda Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06953869)) |
| November 2027 | [Fanapt® (iloperidone) primary completion](https://sec-api.dev/pdufa/iloperidone) | VNDA | Schizophrenia | scheduled | "NCT06961968 (Randomized Withdrawal Study in Patients With Schizophrenia): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-11 (ESTIMATED); Lead Sponsor Vanda Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06961968)) |
| Nov 2027 to Feb 2028 | [Fanapt® (iloperidone) topline data readout](https://sec-api.dev/pdufa/iloperidone) | VNDA | Schizophrenia | scheduled | "NCT06961968 (Randomized Withdrawal Study in Patients With Schizophrenia): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-11 (ESTIMATED); Lead Sponsor Vanda Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06961968)) |
| March 2028 | [BYSANTITM (milsaperidone) primary completion](https://sec-api.dev/pdufa/milsaperidone) | VNDA | Major Depressive Disorder (MDD) | scheduled | "NCT06830044 (Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03 (ESTIMATED); Lead Sponsor Vanda Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06830044)) |
| Mar to Jun 2028 | [BYSANTITM (milsaperidone) topline data readout](https://sec-api.dev/pdufa/milsaperidone) | VNDA | Major Depressive Disorder (MDD) | scheduled | "NCT06830044 (Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03 (ESTIMATED); Lead Sponsor Vanda Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06830044)) |
| August 2028 | [Ponesimod primary completion](https://sec-api.dev/pdufa/ponesimod) | VNDA | Moderate-to-severe Chronic Plaque Psoriasis | scheduled | "NCT07362017 (Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-08 (ESTIMATED); Lead Sponsor Vanda Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07362017)) |
| Aug to Nov 2028 | [Ponesimod topline data readout](https://sec-api.dev/pdufa/ponesimod) | VNDA | Moderate-to-severe Chronic Plaque Psoriasis | scheduled | "NCT07362017 (Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-08 (ESTIMATED); Lead Sponsor Vanda Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07362017)) |
| April 2029 | [Ponesimod primary completion](https://sec-api.dev/pdufa/ponesimod) | VNDA | Ulcerative Colitis (UC) | scheduled | "NCT07686081 (Study to Evaluate the Efficacy and Safety of Ponesimod (VSP-128) in Patients With Moderately to Severely Active Ulcerative Colitis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-04 (ESTIMATED); Lead Sponsor Vanda Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07686081)) |
| Apr to Jul 2029 | [Ponesimod topline data readout](https://sec-api.dev/pdufa/ponesimod) | VNDA | Ulcerative Colitis (UC) | scheduled | "NCT07686081 (Study to Evaluate the Efficacy and Safety of Ponesimod (VSP-128) in Patients With Moderately to Severely Active Ulcerative Colitis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-04 (ESTIMATED); Lead Sponsor Vanda Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07686081)) |

## Drugs

- [Bysanti (bysanti)](https://sec-api.dev/pdufa/bysanti): 
- [Generic](https://sec-api.dev/pdufa/generic): 
- [Fanapt® (iloperidone)](https://sec-api.dev/pdufa/iloperidone): Hypertension, Schizophrenia
- [Imsidolimab](https://sec-api.dev/pdufa/imsidolimab): 
- [BYSANTITM (milsaperidone)](https://sec-api.dev/pdufa/milsaperidone): schizophrenia in adults, Major Depressive Disorder (MDD)
- [Ponesimod](https://sec-api.dev/pdufa/ponesimod): Moderate-to-severe Chronic Plaque Psoriasis, Ulcerative Colitis (UC)
- [HETLIOZ® (tasimelteon)](https://sec-api.dev/pdufa/tasimelteon): jet lag disorder, delayed sleep-wake phase disorder, Sleep Wake Disorders
- [Tasimelteon oral capsule, tasimelteon liquid suspension](https://sec-api.dev/pdufa/tasimelteon-oral-capsule-tasimelteon-liquid-suspension): Autism Spectrum Disorder
- [Tasimelteon oral suspension](https://sec-api.dev/pdufa/tasimelteon-oral-suspension): Insomnia Disorder
- [NEREUSTM (tradipitant)](https://sec-api.dev/pdufa/tradipitant): vomiting induced, symptoms of gastroparesis to a final decision prior, motion sickness, Obesity, Idiopathic Gastroparesis, Nausea and Vomiting
- [Trichostatin a](https://sec-api.dev/pdufa/trichostatin-a): Onychomycosis of Toenail
- [VCA-894A](https://sec-api.dev/pdufa/vca-894a): patient with cmt2s
- [VQW-765](https://sec-api.dev/pdufa/vqw-765): Social Anxiety Disorder (SAD)
- [VSJ-110](https://sec-api.dev/pdufa/vsj-110): Dry Eye
- [VTR-297](https://sec-api.dev/pdufa/vtr-297): onychomycosis, a fungal infection of the nail

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/vnda/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "VNDA catalysts: Vanda Pharmaceuticals Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/vnda/catalysts

```bibtex
@misc{secapidev_companies_vnda_catalysts_20261116,
  title        = {VNDA catalysts: Vanda Pharmaceuticals Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/vnda/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_vnda_catalysts_20261116","title":"VNDA catalysts: Vanda Pharmaceuticals Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/vnda/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
